CAMBRIDGE, Mass.--(BUSINESS WIRE)--Multiply Labs and Portal Biotechnologies announced their collaboration today, combining the efficiency of Multiply Labs’ robotic automation with the differentiated cell engineering capabilities of the Portal platform. This collaboration is an important step forward for cell therapy development and manufacturing with the goal of leveraging automation to accelerate product timelines and reduce costs, helping innovative cell therapies reach more patients..

马萨诸塞州剑桥市。-（商业新闻短讯）--Multiply Labs和Portal Biotechnologies今天宣布合作，将Multiply Labs机器人自动化的效率与门户平台的差异化细胞工程能力相结合。这种合作是细胞疗法开发和制造向前迈出的重要一步，目的是利用自动化加快产品时间表并降低成本，帮助创新细胞疗法惠及更多患者。。

“Cell therapy manufacturing infrastructure and its associated costs have severely limited the accessibility of cell therapies. Multiply Labs’ automation strategy has the potential to modularize and simplify cell therapy production to ensure greater patient impact. We are very excited to contribute to the Multiply Labs team’s vision by integrating our next generation cell engineering approach with their robotics,” said Armon Sharei, Founder and CEO of Portal..

“细胞疗法制造基础设施及其相关成本严重限制了细胞疗法的可及性。Multiple Labs的自动化策略有可能模块化和简化细胞疗法的生产，以确保对患者产生更大的影响。我们很高兴通过将我们的下一代细胞工程方法与机器人技术相结合，为Multiple Labs团队的愿景做出贡献，”门户网站创始人兼首席执行官Armon Sharei说道。。

Portal’s mechanoporation technology has demonstrated the capability to deliver many different types of cargo to a broad range of cell types while preserving normal cell function. By enabling robust multiplexed engineering of cells, this approach can enable a broad range of novel cell therapies. This partnership will add automation support for Portal’s platform and overall approach to intracellular delivery, improving efficiency, throughput, and speed, while reducing the risk of human error.

Portal的机械操作技术已经证明能够将许多不同类型的货物输送到各种细胞类型，同时保持正常的细胞功能。通过实现强大的细胞多重工程，这种方法可以实现广泛的新型细胞疗法。这种合作关系将为门户平台和细胞内递送的整体方法增加自动化支持，提高效率、吞吐量和速度，同时降低人为错误的风险。

The companies aim to develop a Robotic Mechanoporation Cartridge that will contain Portal’s hardware consumable kit, enabling Multiply Labs’ robotic systems to autonomously operate Portal’s mechanoporation technology..

这些公司的目标是开发一种机器人机械操作墨盒，其中将包含Portal的硬件耗材套件，使Multiple Labs的机器人系统能够自主操作Portal的机械操作技术。。

“We are honored to welcome Portal Biotechnologies into our industry-leading partner ecosystem,” said Fred Parietti, PhD, Co-Founder and CEO of Multiply Labs. “It is crucial that we partner with companies like Portal, who are on the cutting edge of drug discovery and cellular therapeutics, to support their scalability through automation.

Multiply Labs联合创始人兼首席执行官Fred Parietti博士说：“我们很荣幸欢迎门户生物技术进入我们业界领先的合作伙伴生态系统。”。“至关重要的是，我们与门户（Portal）等处于药物发现和细胞治疗前沿的公司合作，通过自动化支持其可扩展性。

Together, we are primed to address some of the largest barriers that exist in cell therapy today, ensuring future patients can benefit from the life-saving potential of these treatments.”.

总之，我们已经准备好解决当今细胞治疗中存在的一些最大障碍，确保未来的患者可以从这些治疗的挽救生命的潜力中受益。”。

Multiply Labs’ automation technology for cell therapy manufacturing is a unique approach that is based on being compatible with the leading GMP-grade instruments, consumables, and reagents. In support of this strategy, Multiply Labs recently published pre-print data demonstrating that automated and manual cell expansion processes are statistically equivalent.

Multiply Labs的细胞治疗制造自动化技术是一种独特的方法，它基于与领先的GMP级仪器，耗材和试剂兼容。为了支持这一策略，Multiply实验室最近发布了打印前数据，证明自动和手动细胞扩增过程在统计学上是等效的。

This implies that manufacturers can automate their current cell expansion protocols with minimal alterations and reduced regulatory risk..

这意味着制造商可以自动化其当前的细胞扩增协议，只需进行最小的更改并降低监管风险。。

Many stakeholders in the cell therapy space will benefit from this collaboration by integrating Portal’s cutting-edge solutions while enjoying the advantages of automation, such as cost reduction and increased throughput.

细胞治疗领域的许多利益相关者将通过整合门户的尖端解决方案，同时享受自动化的优势，如降低成本和提高吞吐量，从而从这种合作中受益。

About Portal Biotechnologies:

关于门户生物技术：

Portal is a cell engineering platform company focused on enabling next generation cell engineering and cell analytics across research and clinical applications. The company is implementing a simplified approach to intracellular delivery, focused on accelerating advances enabled by the new generation of RNA, gene editing, and AI-driven technologies.

门户是一家细胞工程平台公司，专注于跨研究和临床应用实现下一代细胞工程和细胞分析。该公司正在实施一种简化的细胞内递送方法，重点是加速新一代RNA，基因编辑和AI驱动技术所带来的进步。

Portal’s initial product suite is based on a proprietary mechanical delivery system capable of delivering many different types of cargo to a broad range of cell types. The technology's ability to be used stand-alone or as an integrated component of third-party systems provides a significant opportunity to broadly impact the fields of biological research and cellular therapeutics.

门户网站的初始产品套件基于专有的机械输送系统，能够将多种不同类型的货物输送到各种细胞类型。该技术能够独立使用或作为第三方系统的集成组件使用，为广泛影响生物学研究和细胞治疗领域提供了重要机会。

About Multiply Labs

关于Multiply Labs

Multiply Labs is a robotics company that provides autonomous manufacturing technology to the pharmaceutical industry. The company develops advanced, cloud-controlled robotic systems that enable the production of individualized drugs at scale. Its customers include some of the largest global organizations in the advanced pharmaceutical manufacturing space.

Multiply Labs是一家机器人公司，为制药行业提供自主制造技术。该公司开发了先进的云控制机器人系统，可以大规模生产个性化药物。其客户包括先进制药制造领域的一些最大的全球组织。

Multiply Labs’ expertise is at the intersection of robotics and biopharma – its team includes mechanical engineers, electrical engineers, computer scientists, software engineers and pharmaceutical scientists. The founding team got in touch because of their shared love of robots at MIT. The company is based in San Francisco, California.

Multiply Labs的专业知识是机器人技术和生物制药的交叉点，其团队包括机械工程师、电气工程师、计算机科学家、软件工程师和制药科学家。由于麻省理工学院对机器人的共同热爱，创始团队取得了联系。该公司总部位于加利福尼亚州旧金山。